BioTuesdays

Category - Markets

Connect-Biopharma-Logo
Markets

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12. Connect is a clinical-stage biotech headquartered in...

April 13, 2021
Gain-Therapeutics-Logo
Markets

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

April 12, 2021
Diagnos-Logo
Markets

Echelon pegs DIAGNOS as Q2 “top picks portfolio”

Echelon Capital Markets added DIAGNOS (TSXV:ADK) to its second quarter “top picks portfolio.” Analyst Stefan Quenneville rates the stock as “speculative buy” with a price target of 85 cents. The stock was quoted at 53...

April 8, 2021
Mesoblast Logo
Markets

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

April 7, 2021
Prometheus-Biosciences-Logo
Markets

Analysts start Prometheus Biosciences at OP and buy

Analysts for Stifel and SVB Leerink initiated coverage of Prometheus Biosciences (NASDAQ:RXDX) with “outperform” and “buy” ratings, respectively, and price targets of $25 and $34, respectively. The stock closed at $19...

April 6, 2021
Longbaord-Pharmaceuticals
Markets

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

April 6, 2021
EyeGate Pharmaceuticals
Markets

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

March 31, 2021
Lineage-Cell-Therapeutics-Logo
Markets

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

March 31, 2021